Event Update: Agenda for Symposium on Translation of Stem Cells into Clinical Stem Cell Therapeutics

November 10, 2008

NATIONAL ACADEMIES HUMAN EMBRYONIC STEM CELL RESEARCH ADVISORY COMMITTEE
Symposium on Translation of Stem Cells into Clinical Stem Cell Therapeutics 
Thursday, November 20, 2008 
National Academy of Sciences  •  Auditorium 
2100 C Street, N.W.  •  Washington, D.C. 20418 

Draft Agenda:

8:00 a.m. Registration

8:30 a.m. Welcome and Introduction of Key Issues 
• R. Alta Charo (committee co-chair), Warren P. Knowles Professor of Law and Bioethics, 
University of Wisconsin–Madison 
• Richard O. Hynes (committee co-chair), Daniel K. Ludwig Professor for Cancer Research 
and Howard Hughes Medical Institute investigator, Massachusetts Institute of Technology 

9:00 a.m. Session 1: Regulatory issues associated with stem cell therapeutics 
Perspective from the U.S. Food and Drug Administration 
• Deborah A. Hursh, Senior Investigator, Division of Cellular and Gene Therapies, Center 
for Biologics Research and Review, U.S. Food and Drug Administration 
Unique issues associated with stem cell therapeutics 
• Darin J. Weber, Senior Consultant, Cell & Gene Therapies, Biologics Consulting Group, Inc. 

10:00 a.m. Break 

10:15 a.m. Session 2: Case Study on Treatment of Heart Disease 
State of knowledge on clinical applications 
• Richard T. Lee, Department of Medicine, Brigham and Women’s Hospital, and Associate 
Professor of Medicine, Harvard Medical School 
Use of animal models to cardiovascular application 
• Christine Mummery, Department of Anatomy and Embryology, Leiden University 
Medical Center 
Technical and clinical challenges in stem cell therapeutics 
• Kenneth Chien, Scientific Director, Cardiovascular Research Center, Massachusetts 
General Hospital; Harvard Stem Cell Institute; Charles Addison and Elizabeth Ann 
Sanders Professor of Medicine and Professor of Cell Biology, Harvard Medical School and 
Harvard Stem Cell Institute 

12:15 p.m. Lunch 

1:15 p.m. Session 3: Case Study on the Treatment of Parkinson’s Disease 
A clinician’s view on stem cell therapies for Parkinson’s Disease 
• Olle Lindvall, Professor of Neurology, Laboratory of Neurogenesis and Cell Therapy, 
Wallenberg Neuroscience Center, Lund University Hospital, Sweden 
Research challenges of stem cell therapeutics 
• Lorenz Studer, Director, Laboratory of Stem Cell & Tumor Biology, and Associate 
Member, Memorial Sloan-Kettering Cancer Center 
Ethical concerns of stem cell therapeutics for Parkinson’s Disease 
• Lawrence S.B. Goldstein, Howard Hughes Medical Institute Investigator, Professor of 
Cellular and Molecular Medicine, and Director, UCSD Stem Cell Program, University of 
California, San Diego 

3:15 p.m. Break

3:30 p.m. Session 4: General issues in stem cell therapeutics 
Moderator:  Susan L. Solomon, Co-founder and Chief Executive Officer, The New York Stem Cell 
Foundation 
• Insoo Hyun, Associate Professor of Bioethics, Case Western Reserve University; Co-Chair, 
Task Force on Clinical Translation of Stem Cells and Chair, Ethics and Public Policy 
Committee, International Society for Stem Cell Research 
• Jane S. Lebkowski, Senior Vice President of Tissue Regenerative Medicine, Geron 
Corporation 
• Amy Comstock Rick, Chief Executive Officer, Parkinson’s Action Network; President, 
Coalition for the Advancement of Medical Research 
• Jeremy Sugarman, Harvey M. Meyerhoff Professor of Bioethics and Medicine, Professor of 
Medicine, Professor of Health Policy and Management, and Deputy Director for Medicine, 
Berman Institute of Bioethics, Johns Hopkins University 

5:00 p.m. Additional discussion and public comment 

5:30 p.m. Symposium adjourns